Clinical Trials
13 trialsNCT04637009 2024-08-02
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
Astex Pharmaceuticals, Inc.
Phase 1 Terminated
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT04480086 2023-08-29
Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis
AbbVie
Phase 1 Terminated
NCT01014546 2022-07-22
Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis
Roswell Park Cancer Institute
Phase 1 Terminated
NCT01300611 2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1 Terminated
NCT02728700 2018-09-12
Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT
Stanford University
Phase 1 Terminated
NCT00852709 2018-02-15
POE07-01
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT00376519 2017-12-02
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT00004239 2016-07-04
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
Alliance for Clinical Trials in Oncology
Phase 1 Terminated
NCT00800150 2015-06-08
Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment
City of Hope Medical Center
Phase 1 Terminated
NCT01291784 2014-12-08
Anti-TGF-beta Therapy in Patients With Myelofibrosis
Icahn School of Medicine at Mount Sinai
Phase 1 Terminated
NCT00522574 2011-04-05
A Safety Study of XL019 in Adults With Myelofibrosis
Exelixis
Phase 1 Terminated
NCT00004058 2010-01-26
12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
Rutgers, The State University of New Jersey
Phase 1 Terminated